someone explain CagriSema to me like I have not read a paper in years
someone explain CagriSema to me like I have not read a paper in years, and I want the answer with the reasoning attached rather than just the conclusion.
Why this compound is not simply another agonist, which is how it gets described everywhere else.
Amylin is co-secreted with insulin and signals satiety through its own receptor complexes. It is a different axis from the incretin system, not a parallel version of it. That is why the combination story is interesting: two mechanisms that address appetite differently, rather than more agonism at one receptor.
It is also why the dosing intuitions people bring from the semaglutide and tirzepatide boards do not transfer. Different receptors, different exposure-response, and no published schedule anybody here can reason from.
Kept a log purely because so few people are logging this one. It is one person and it is not data.
Asked a question here that turned out to be based on a mechanism confusion. Three people untangled it patiently.
If two or three other people have done the same thing we might actually learn something. Alone it is an anecdote.
best — the order this archive was captured in
Complementary mechanisms are the rationale for pairing: satiety signalling alongside incretin signalling, rather than more agonism at the same receptor.
[deleted]
this is a less-travelled board and the evidence base shows it
The tolerability tables were more informative than the headline numbers, which is usually the case and never how it gets summarised.
Independent purity data on this compound is sparse compared with the older molecules, simply because far fewer members have paid for testing. Sparse data means wide uncertainty, not a verdict.
Right, and the tolerability data in the combination arms is the part worth reading properly rather than summarising.
Monotherapy arm or combination arm?
Bought small deliberately because the evidence base is thin. That felt like the only defensible approach.
independent purity data on this compound is thin
That is preclinical work and the thread is treating it as a human finding.
Agreed that the monotherapy numbers look modest out of context and that the context is the whole story.
Small fix — amylin analogue, not a GLP-1 analogue. The whole mechanism argument changes on that word.
Agreed — it is an amylin analogue and importing intuitions from the incretin boards produces confident nonsense.
Combination and monotherapy arms must be read separately. Efficacy and tolerability both differ substantially between them and summaries routinely blur the two.
the interesting data is the combination, not the monotherapy
Do you have the publication or a summary of it?
Read the combination paper twice before saying anything here. The monotherapy and combination arms tell genuinely different stories.
Push back: the evidence base here is thin enough that a confident ranking against the established compounds is not supportable.
Standing reminder: nothing here is approved standalone, research material is not for human use, and no dosing schedules for other members.
Which receptor family are you attributing that effect to?
Which receptor family are you attributing that effect to?
Agreed, and the combination arms are where the interesting numbers actually live.
Correction: that is the combination programme, not the monotherapy readout. Different arms, different numbers.
- 1That is preclinical work and the thread is treating it as a human finding.6 comments in this branch · started by u/elin_lundgren